Citius Oncology Enters Material Definitive Agreement
Ticker: CTOR · Form: 8-K · Filed: Sep 13, 2024 · CIK: 1851484
Sentiment: neutral
Topics: material-definitive-agreement, new-deal
TL;DR
Citius Oncology signed a big deal, details TBD.
AI Summary
On September 9, 2024, Citius Oncology, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, the other party involved, or any associated financial figures.
Why It Matters
This filing indicates a significant new agreement for Citius Oncology, which could impact its future operations and financial performance, though details are currently undisclosed.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the nature and terms of the material definitive agreement introduces uncertainty.
Key Players & Entities
- CITIUS ONCOLOGY, INC. (company) — Registrant
- September 9, 2024 (date) — Date of earliest event reported
- 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (address) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement entered into by Citius Oncology, Inc.?
The filing states that Citius Oncology, Inc. entered into a Material Definitive Agreement on September 9, 2024, but does not provide specific details about its nature.
Who is the other party to this Material Definitive Agreement?
The filing does not disclose the name of the other party involved in the Material Definitive Agreement.
Are there any financial terms or dollar amounts associated with this agreement?
The provided excerpt of the filing does not mention any specific financial terms or dollar amounts related to the Material Definitive Agreement.
When was this Material Definitive Agreement entered into?
The Material Definitive Agreement was entered into on September 9, 2024.
What is the primary business of Citius Oncology, Inc.?
Citius Oncology, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-09-13 08:30:09
Filing Documents
- ea0214419-8k_citius.htm (8-K) — 25KB
- 0001213900-24-078287.txt ( ) — 195KB
- ctor-20240909.xsd (EX-101.SCH) — 3KB
- ctor-20240909_lab.xml (EX-101.LAB) — 33KB
- ctor-20240909_pre.xml (EX-101.PRE) — 22KB
- ea0214419-8k_citius_htm.xml (XML) — 4KB
01. Entry into a Material Definitive
Item 1.01. Entry into a Material Definitive Agreement. Pending further discussions with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's"), Dr. Reddy's agreed to a partial deferral without penalty of a milestone payment by Citius Oncology, Inc. (the "Company"), which was triggered upon regulatory approval of LYMPHIR TM by the U.S. Food and Drug Administration and due on September 9, 2024, pursuant to the terms of the Asset Purchase Agreement, dated as of September 1, 2021, between Dr. Reddy's and Citius Pharmaceuticals, Inc. (the "Asset Purchase Agreement"). Except as set forth above, all other terms, conditions and rights of the Asset Purchase Agreement remain in full force and effect, which description was incorporated by reference into Current Report on Form 8-K filed by the Company on August 16, 2024. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CITIUS ONCOLOGY, INC. Date: September 13, 2024 /s/ Leonard Mazur Leonard Mazur Chairman and Chief Executive Officer 2